- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03380377
Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant
A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) As an Agent to Eliminate Donor Specific HLA Antibodies and Improve Outcomes of Patients With Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single center, Phase I/II, open label single-arm exploratory study. The trial will primarily examine the safety and tolerability of clazakizumab given after the diagnosis of cABMR in 10 subjects (15-75yrs) who exhibit DSAs to their donor. Patients entered will also have been diagnosed with cABMR + TG post-transplant based on Banff 2015 criteria. Patients are required to have a eGFR > 30 mL/min/1.73m2 as calculated by the MDRD equation (Schwartz equation will be used to estimate CrCl for patients under 18 years of age) at entry. All patients will be recruited from the renal transplant program at Cedars-Sinai Medical Center. Once cABMR is diagnosed, donor-specific anti-HLA antibodies will be assessed (DSA) which are associated with cABMR and/or graft loss. DSA will be detected using solid phase assay systems currently utilized at the Cedars-Sinai Medical Center HLA Laboratory (Dr. Xiaohai Zhang Director, Phone: 310-423-4979)41. These anti-HLA antibodies may result naturally or from previous pregnancy, transfusions, or prior transplants. Patients treated with clazakizumab for cABMR will have labs for DSAs, and other monitoring labs as well as immunologic studies as outlined. In addition to the standard post-transplant immunosuppressive protocol, patients with cABMR will receive clazakizumab 25mg SC given every 4 weeks (30 days) for a total of 6 doses. If no safety/tolerability/efficacy issues are observed after the initial dose, patients will continue the protocol as outlined. A protocol biopsy will be performed after the 6th and after the 12th doses of clazakizumab to assess the allograft for evidence of cABMR/ABMR, including C4d staining and TG using Banff 2015 criteria14. Banff scoring will be compared between the index and protocol biopsy after cessation of therapy. Patients who have evidence of persistent allograft dysfunction may have non-protocol biopsies for cause. After completion of the clazakizumab therapy, patients will be followed up to assess allograft function and ABMR episodes as well as DSAs. The protocol is summarized in figure 14 below. Monitoring of Treg, Th17, Tfh and plasmablast as well as IL-6, and CRP levels will be performed in the Transplant Immunology Lab at Cedars-Sinai Medical Center at select time points (Dr. Mieko Toyoda Director, Phone: 310-423-8282). confirmation) they will continue monthly clazakizumab for an additional 6 months and will have a second biopsy at 12 month protocol. Immunologic and viral monitoring labs will be performed as indicated.
The subjects will be followed to determine if the use of clazakizumab for treatment of cABMR in this high-risk transplant population is safe and without infectious risks. In addition, the investigators will determine the effects of clazakizumab treatment on renal biopsy assessments performed at 6 months. Assessments of renal function, donor specific antibody, and Banff 2015 biopsy scores will be evaluated at that time. If improvement or stabilization observed, clazakizumab will be resumed monthly x 6 doses (starting day 180 to day 330) and last study visit will be day 365 with biopsy. Study investigators will assess the transplanted patients to determine the number who sustain a viable and functioning kidney allograft as well. In the event a patient does not show improvement after receiving 6 doses of clazakizumab, no further treatment will be given and the patient will return at Day 365 for a final study visit. All subjects will be evaluated on an intent-to-treat basis. The subject accrual rate will be limited to no more than 1-2 subjects per month in the initial three months to assure safety to all subjects. Repeat laboratories will be performed at the completion of clazakizumab therapy to determine effect on levels and correlation with any potential events.
Long term dosing option at conclusion of 12 months (after Study Day 365 visit) will be available for those patients who complete the 12 month protocol. Patients may continue to receive clazakizumab 25 mg subQ every 8 weeks long term, per PI discretion.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Norko Ammerman
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 15-75 years at the time of screening.
- Biopsy proven cABMR with TG on biopsy as defined by Banff 2015 and DSA positive at time of biopsy
- Subject/Parent/Guardian must be able to understand and provide informed consent.
- Pneumococcal vaccinated
- Negative tuberculin ppd result or negative Quantiferon TB gold
Exclusion Criteria:
- Multi-organ transplant (e.g. kidney and pancreas)
- eGFR < 30 mL/min/1.73m2
- Advanced Transplant Glomerulopathy (CG3)
- Previous allergic reactions to monoclonal antibodies.
- Lactating or pregnant females.
- Women of child-bearing age who are not willing or able to practice FDA-approved forms of contraception during study and for 5 months after last dose.
- HIV-positive subjects.
- Subjects who test positive for HBV by HBVeAg/DNA or HCV infection [positive Anti-HCV (EIA) and confirmatory HCV RIBA].
- Subjects with latent or active TB. Subjects must have negative Quantiferon TB gold test result.
- Recent recipients of any licensed or investigational live attenuated vaccine(s) within two months of the screening visit j) A significantly abnormal general serum screening lab result defined as a WBC < 3.0 X 103/ml, a Hgb < 8.0 g/dL, a platelet count < 100 X 103/ml, an SGOT or SGPT > 3X upper limit normal
- Individuals deemed unable to comply with the protocol.
- Subjects with active CMV or EBV infection as defined by CMV-specific serology (IgG or IgM) and confirmed by quantitative PCR with or without a compatible illness.
- Use of investigational agents within 4 weeks of participation.
- History or active Inflammatory Bowel Disease or Diverticular Disease or gastrointestinal perforation
- Recent infection (within past 6 weeks of screening) requiring any antibiotic use (oral, parenteral or topical).
- Present or previous (within 5 years) malignancy except for basal cell carcinoma, fully excised squamous cell carcinoma of the skin or non-recurrent (within 5 years) cervical carcinoma-in-situ.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Clazakizumab (Anti-IL-6 Monoclonal)
All ten patients will be receiving clazakizumab (Anti-IL-6 Monoclonal) monthly for six months.
Then patients will be scheduled for six month protocol biopsy.
If biopsy and all clinical labs show benefit or stability (up to PI discretion), patients will continue receiving clazakizumab monthly for another six months.
All patients completing twelve doses of clazakizumab will be scheduled for a twelve month protocol biopsy and last study visit.
If at the 6 month protocol biopsy, no improvement was seen, PI will have patient come for their last study visit on month 12 post enrollment.
|
Clazakizumab 25 mg subcutaneous monthly x 6 doses (or max of 12 doses) will be given to patients who are enrolled in this clinical trial.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Donor specific antibody elimination based on luminex HLA testing
Time Frame: 12 months
|
Does clazakizumab eliminate or weaken donor specific antibodies intensities.
|
12 months
|
Stabilization of clinical features of cABMR via BANFF biopsy grading criteria.
Time Frame: 12 months
|
Does clazakizumab help stabilize pathologic features of antibody mediated rejection at 6 month and 12 month protocol biopsies?
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum creatinine
Time Frame: 12 months
|
Serum creatinine (mg/dl) will be collected at multiple time points throughout the study to calculate eGFR
|
12 months
|
Immunologic markers
Time Frame: 12 months
|
Immunologic markers collected at multiple time points throughout the study
|
12 months
|
Incidence of treatment-related adverse events
Time Frame: 12 months
|
Adverse event monitoring, assessment of labs, monitoring of viral PCRs
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stanley Jordan, MD, Cedars-Sinai Medical Center Comprehensive Transplant Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 134733
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplant Rejection
-
University of MinnesotaCompletedKidney Transplant Rejection | Kidney Transplant; Complications | Transplant; Complication, Rejection | Kidney Transplant Failure and Rejection | Transplant DysfunctionUnited States
-
Natera, Inc.RecruitingKidney Transplant Rejection | Kidney Transplant; Complications | Allograft RejectionUnited States
-
Rush University Medical CenterCareDxCompletedKidney Transplant Rejection | Pancreas Transplant RejectionUnited States
-
Charite University, Berlin, GermanyActive, not recruitingKidney Transplant Rejection | Antibody-mediated Rejection | Kidney Transplant FailureGermany
-
Ajay IsraniNational Institute of Allergy and Infectious Diseases (NIAID)Active, not recruitingKidney Transplant Rejection | Kidney TransplantUnited States
-
Hospital de Clinicas de Porto AlegreActive, not recruitingKidney Transplant Infection | Kidney Transplant Rejection | Kidney Transplant Failure | Kidney Transplant Failure and RejectionBrazil
-
University of MinnesotaWithdrawnKidney Transplant Rejection | Kidney Transplant; Complications | Kidney Transplant FailureUnited States
-
Columbia UniversityVeloxis PharmaceuticalsActive, not recruitingRenal Transplant Rejection | Kidney Transplant Failure and RejectionUnited States
-
Viela Bio (acquired by Horizon Therapeutics)CompletedKidney Transplantation | Transplant Rejection | Allografts | Rejection; Transplant, KidneyUnited States
-
University of LiegeRecruitingKidney Transplant Rejection | Kidney Transplant; ComplicationsBelgium
Clinical Trials on Clazakizumab
-
Cedars-Sinai Medical CenterCompleted
-
Medical University of ViennaCharite University, Berlin, Germany; University of Alberta; CSL BehringCompleted
-
NYU Langone HealthCompleted
-
Columbia UniversityNYU Langone Health; CSL BehringTerminated
-
Anne B. NewmanCSL BehringRecruitingImproving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study (RIGHT)Inflammation | FrailtyUnited States
-
The Methodist Hospital Research InstituteUnknown
-
CSL BehringCompletedRheumatoid ArthritisItaly, United States, France, Argentina, Mexico, Japan, Canada, Hungary, South Africa
-
CSL BehringActive, not recruitingEnd Stage Kidney Disease | Atherosclerotic Cardiovascular DiseaseUnited States, Australia, Belgium, Canada, Germany
-
Stanley Jordan, MDActive, not recruitingKidney Failure, Chronic | End-Stage Renal Disease | Kidney Transplant; Complications | Antibody-mediated Rejection | Kidney Transplant Failure and Rejection | Transplant;Failure,Kidney | Transplant GlomerulopathyUnited States
-
CSL BehringTerminatedCrohn's DiseaseGermany, India, Korea, Republic of, Taiwan, United States, Hong Kong, Canada, Mexico, Austria, Switzerland, Israel, Italy, France, Poland, Netherlands, Hungary, Czechia, United Kingdom